These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 38662093)

  • 1. Ketamine and its enantiomers for depression: a bibliometric analysis from 2000 to 2023.
    Zhao LY; Zhang GF; Lou XJ; Hashimoto K; Yang JJ
    Eur Arch Psychiatry Clin Neurosci; 2024 Apr; ():. PubMed ID: 38662093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global Trends and Hotspots in Esketamine Research: A Bibliometric Analysis of Past and Estimation of Future Trends.
    Li X; Xiang P; Liang J; Deng Y; Du J
    Drug Des Devel Ther; 2022; 16():1131-1142. PubMed ID: 35478936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A historical review of antidepressant effects of ketamine and its enantiomers.
    Wei Y; Chang L; Hashimoto K
    Pharmacol Biochem Behav; 2020 Mar; 190():172870. PubMed ID: 32035078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bibliometric analysis of research on (R)-ketamine from 2002 to 2021.
    He T; Wang D; Wu Z; Huang C; Xu X; Xu X; Liu C; Hashimoto K; Yang C
    Neuropharmacology; 2022 Nov; 218():109207. PubMed ID: 35948160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).
    Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB
    Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.
    Wei Y; Chang L; Hashimoto K
    Mol Psychiatry; 2022 Jan; 27(1):559-573. PubMed ID: 33963284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.
    Hashimoto K
    Biochem Pharmacol; 2020 Jul; 177():113935. PubMed ID: 32224141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketamine: A tale of two enantiomers.
    Jelen LA; Young AH; Stone JM
    J Psychopharmacol; 2021 Feb; 35(2):109-123. PubMed ID: 33155503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
    Hashimoto K
    Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antidepressant actions of ketamine and its enantiomers.
    Johnston JN; Henter ID; Zarate CA
    Pharmacol Ther; 2023 Jun; 246():108431. PubMed ID: 37146727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A scientometric analysis of research on the role of NMDA receptor in the treatment of depression.
    Chen X; Wang X; Li C; Zhang Y; Feng S; Xu S
    Front Pharmacol; 2024; 15():1394730. PubMed ID: 38974036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacology of ketamine and esketamine as rapid-acting antidepressants].
    Pavlidi P; Megalokonomou A; Sofron A; Kokras N; Dalla C
    Psychiatriki; 2021 Dec; 32(Supplement I):55-63. PubMed ID: 34990380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the Molecular Targets for the Antidepressant and Antisuicidal Effects of Ketamine Enantiomers by Using Network Pharmacology and Molecular Docking.
    Altê GA; Rodrigues ALS
    Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on ketamine and its two enantiomers as rapid-acting antidepressants.
    Zhang K; Hashimoto K
    Expert Rev Neurother; 2019 Jan; 19(1):83-92. PubMed ID: 30513009
    [No Abstract]   [Full Text] [Related]  

  • 16. Arketamine, a new rapid-acting antidepressant: A historical review and future directions.
    Zhang JC; Yao W; Hashimoto K
    Neuropharmacology; 2022 Nov; 218():109219. PubMed ID: 35977629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An examination of Alzheimer's disease and white matter from 1981 to 2023: a Bibliometric and visual analysis.
    Wu L; Jin L; Li L; Yu K; Wu J; Lei Y; Jiang S; He J
    Front Neurol; 2023; 14():1268566. PubMed ID: 38033779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Bibliometric Analysis of Research on Ketamine From 2001 to 2020.
    Miao H; Yu K; Gao D; Lin X; Cao Y; Liu X; Qiao H; Li T
    Front Mol Neurosci; 2022; 15():839198. PubMed ID: 35283728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (S)-Ketamine but Not (R)-Ketamine Shows Acute Effects on Depression-Like Behavior and Sleep-Wake Architecture in Rats.
    Koncz S; Papp N; Pothorszki D; Bagdy G
    Int J Neuropsychopharmacol; 2023 Sep; 26(9):618-626. PubMed ID: 37578355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review.
    Boudieu L; Mennetrier M; Llorca PM; Samalin L
    Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.